CT Cullinan Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Cullinan Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.3bn. The latest transaction was disclosed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Michaelson Jennifer. Every trade is openly available.
Analyst consensus: bullish or bearish? Analysts rate Cullinan Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$32.36.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
All Executives59 Thresholds0 Prospectus0 Other0
Declarations 59 total
● Officer · Executives · 8 Sept 2026
8,000 shares @ US$22.09 Common SEC144:0001950047-26-009190
▼ Chief Scientific Officer · Executives · 13 Aug 2026
30,000 shares @ US$20.26 0.050% mcap 29.6% of flow Common Stock SEC:0001193125-26-352523:1
◇ Chief Scientific Officer · Executives · 13 Aug 2026
30,000 shares @ US$4.30 0.011% mcap 6.3% of flow Common Stock SEC:0001193125-26-352523:0
● Officer · Executives · 13 Aug 2026
30,000 shares @ US$19.60 0.049% mcap 80.5% of flow Common SEC144:0001950047-26-008087
◇ Chief Scientific Officer · Executives · 6 Jul 2026
4,000 shares @ US$4.30 0.0014% mcap 1.7% of flow Common Stock SEC:0001193125-26-297605:0
▼ Chief Scientific Officer · Executives · 6 Jul 2026
8,000 shares @ US$17.82 0.012% mcap 13.9% of flow Common Stock SEC:0001193125-26-297605:1
● Officer · Executives · 6 Jul 2026
8,000 shares @ US$17.63 0.012% mcap 100.0% of flow Common SEC144:0001950047-26-006865
◇ Chief Scientific Officer · Executives · 5 Mar 2026
4,000 shares @ US$4.30 1.3% of flow Common Stock SEC:0001193125-26-098781:0
▼ Chief Scientific Officer · Executives · 25 Feb 2026
1,780 shares @ US$14.14 1.9% of flow Common Stock SEC:0001193125-26-077259:0
▼ Chief Scientific Officer · Executives · 23 Feb 2026
1,752 shares @ US$13.99 1.8% of flow Common Stock SEC:0001193125-26-072002:0
▼ President and CEO · Executives · 24 Feb 2026
13,515 shares @ US$14.47 26.0% of flow Common Stock SEC:0001193125-26-072001:0
▼ Chief Medical Officer · Executives · 24 Feb 2026
4,582 shares @ US$14.47 23.2% of flow Common Stock SEC:0001193125-26-072000:0
▼ Chief Legal Officer · Executives · 24 Feb 2026
3,601 shares @ US$14.47 23.9% of flow Common Stock SEC:0001193125-26-071997:0
▼ Chief Financial Officer · Executives · 20 Feb 2026
4,398 shares @ US$13.62 99.7% of flow Common Stock SEC:0001193125-26-064261:0
▼ Chief Medical Officer · Executives · 20 Feb 2026
4,982 shares @ US$13.62 23.8% of flow Common Stock SEC:0001193125-26-064257:0
▼ Chief Scientific Officer · Executives · 20 Feb 2026
3,742 shares @ US$13.62 3.8% of flow Common Stock SEC:0001193125-26-064256:0
▼ Chief Legal Officer · Executives · 20 Feb 2026
3,742 shares @ US$13.62 23.5% of flow Common Stock SEC:0001193125-26-064255:0
▼ President and CEO · Executives · 20 Feb 2026
16,381 shares @ US$13.62 29.7% of flow Common Stock SEC:0001193125-26-064254:0
◆ Chief Financial Officer · Executives · 18 Feb 2026
68,750 shares 0Common Stock SEC:0001193125-26-059637:0
◆ Chief Scientific Officer · Executives · 18 Feb 2026
57,500 shares 0Common Stock SEC:0001193125-26-059636:0
▼ Chief Scientific Officer · Executives · 12 Feb 2026
416 shares @ US$12.03 0.4% of flow Common Stock SEC:0001193125-26-051700:0
▼ Chief Scientific Officer · Executives · 22 Jan 2026
4,000 shares @ US$12.30 3.7% of flow Common Stock SEC:0001193125-26-021225:0
◆ Chief Financial Officer · Executives · 31 Dec 2025
27 shares @ US$6.49 0.3% of flow Common Stock SEC:0001193125-26-002687:0
▼ President and CEO · Executives · 23 Dec 2025
9,922 shares @ US$10.01 29.9% of flow Common Stock SEC:0001193125-25-335482:0
▼ Chief Scientific Officer · Executives · 19 Dec 2025
1,345 shares @ US$10.01 1.2% of flow Common Stock SEC:0001193125-25-328909:0
25 of 59 declarations
Load more (34 remaining) 关于 Cullinan Therapeutics, Inc. Cullinan Therapeutics, Inc. 是一家生物制药公司，专注于开发创新的癌症治疗方法。该公司致力于发现和开发针对特定疾病机制的药物。